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ABSTRACT 
Purpose 
To compare the use of 18F-fluorodeoxyglucose positron emission tomography with computed 
tomography (FDG PET/CT) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging 
(DCE-MRI) to predict prognosis and monitor treatment in Malignant Pleural Mesothelioma. 
Methods  
FDG PET/CT and DCE-MRI studies carried out as part of the South West Area 
Mesothelioma Pemetrexed (SWAMP) trial were used. FDG PET/CT and DCE-MRI studies 
were carried out before treatment, and after two cycles of chemotherapy, on patients treated 
with Pemetrexed and Cisplatin. 73 patients were recruited, of whom 65 had PET/CT and 
DCE-MRI scans. Baseline measurements from FDG PET/CT (SUVmax, Metabolic Tumour 
Volume (MTV) and Total Lesion Glycolysis (TLG)) and DCE-MRI (Integrated Area Under the 
first 90s of the curve (IAUC90) and washout slope) were compared with overall survival (OS) 
using Kaplan Meier and Cox regression analysis, and change in imaging measurements 
were compared with disease progression. 
Results 
PET/CT and DCE-MRI measurements were not correlated with each other. SUVmax, MTV 
and TLG were significantly related to OS with Cox Regression and analysis and Kaplan-Meir 
analysis, and DCE-MRI washout curve shape was significantly related to overall survival. 
DCE-MRI curve shape can be combined with FDG PET/CT to give additional prognostic 
information. Changes in measurements were not related to progression free survival. 
Conclusions 
FDG-PET/CT and DCE-MRI give prognostic information in Malignant Pleural Mesothelioma. 
Neither PET/CT nor DCE-MRI are useful for monitoring disease progression. 
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Introduction 
Malignant Pleural Mesothelioma (MPM) is caused by exposure to asbestos 
dust. There is a long latency period, typically 30 to 40 years, between 
exposure and development of the disease, so incidence continues to rise 
long after asbestos use has finished. Death rates in Great Britain have 
continued to increase [1], from 24.6 per million for men and 3.3 per million 
for women in 1984-1986, to 68.2 and 12.7 deaths per million in 2011-2013; 
death rates are expected to level off over the next decade. Patients with 
MPM have a life expectancy of only 9-14 months following diagnosis [2]. 
Chemotherapy with Pemetrexed and Cisplatin [3] has been shown to have 
a significant survival benefit.  
The South West Area Mesothelioma and Pemetrexed Trial (SWAMP) [4] 
was designed to examine the use of imaging with 18F-Fluorodeoxyglucose 
PET/CT to predict overall survival from baseline imaging, and to correlate 
changes in PET/CT with progression free-survival. Dynamic Contrast-
Enhanced MRI (DCE-MRI) was carried out on patients on the same day as 
PET/CT, but not used as a primary or secondary outcome measure due to 
the lack of established evidence to define responders and non-responders. 
The aim of this sub-study is to compare FDG-PET/CT and DCE-MRI 
parameters at baseline, in comparison with overall survival, and compare 
change with radiological progression. 
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Materials and Methods 
Patients 
73 patients with biopsy proven MPM were recruited over three years from 
2008 to 2011 at seven centres under the South West Area Mesothelioma 
and Pemetrexed (SWAMP) trial [4]. Ethical and regulatory approval for the 
study was obtained before recruitment commenced (UK REC Reference: 
08/H0102/46), and all subjects signed a written informed consent form. The 
trial was registered in the UK national portfolio (UKCRN ID:8450). Inclusion 
criteria were a life expectancy exceeding three months, and no previous 
debulking surgery or other radical therapy.  
All patients were offered chemotherapy with Pemetrexed and Cisplatin or 
Carboplatin by the oncologist responsible for their clinical care. 58 patients 
had chemotherapy, while 15 patients who declined chemotherapy received 
best supportive care. Overall Survival (OS) was measured from recruitment 
until death or the study closed, 12 months after the last patients were 
recruited. All patients were offered imaging at study entry and after 6 
weeks, following two cycles of chemotherapy.  
Imaging 
FDG PET/CT scans and DCE-MRI scans were conducted in the same half-
day appointment at a single imaging centre; all patients were offered both. 
The DCE-MRI scan was undertaken before the FDG PET/CT to minimise 
radiation exposure of clinical staff. Trial scans were stored without direct 
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identification to the patient and results were not accessible to oncologists 
responsible for their care. 
Progression was determined from CT scans carried out separately, but 
scored centrally, using the modified RECIST criteria [5]. 
DCE-MRI 
Patients were screened for contraindications to MRI scanning by both the 
clinical trials team and experienced radiographers, and imaged on a 1 
Tesla High Field Open System (Philips Medical Systems, Best, The 
Netherlands). 
Patients were scanned using a fat-saturated T1W axial sequence covering 
the entire lungs from just above the apices to just below the bases – usually 
achieved with around 70 contiguous slices of 4mm thickness. There were 
20 phases – 1 pre-contrast and 19 post-contrast. The frame time was 45-
55s, depending on the imaging field of view. 15ml Gadolinium-based contrast (gadoteric acid) was injected 
at a rate of 1ml per sec. 
PET/CT acquisition  
PET/CT scans were performed using a Gemini – GXL scanner (Philips 
Medical Systems, Best, The Netherlands) with Brilliance 16 slice CT. 
Patients were nil by mouth for 6 hours prior to the injection of 400 MBq 
FDG. Blood sugar was checked to be within normal range prior to injection. 
A 90-minute uptake period was allowed.  PET images were corrected for 
photon attenuation using the CT scan and normalized by body weight. The 
QA of the PET/CT scanner was carried out according to best accepted 
practice in the UK. 
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DCE-MRI image and curve analysis 
A method for Region of Interest (ROI) definition was developed, based on 
Giesel et al [6, 7]. A similar method has been described for a study of 
Zoledronic acid in pleural disease [8]. The tumor was identified on the T1 
image (figure 1A), taking account of the enhancement image by a 
consensus of two radiologists experienced in DCE-MRI analysis. A 
freehand ROI was defined on a single slice around the pleural tumor at the 
level with the largest clearly definable area of tumor on the Philips 
workstation, taking care to exclude normal lung. A graph of image intensity 
against frame was generated for each ROI and image sequence (figure 
1B). 
The curve data was transferred as a text file from the Philips workstation to 
a spreadsheet programme (Microsoft Excel). The time from baseline image 
to the first enhanced image varied, so t=0 was taken to be one frame length 
before the first enhancement point.  
From the percentage enhancement-time curve the Integrated Area Under 
Curve in the first 90s (IAUC90) and the washout slope (change in percent 
enhancement/minute) from 4-8 minutes were calculated. The area under 
the curve was calculated using the trapezium rule, and the change between 
data points was assumed to be linear for calculations of area under curve. 
The washout slope was further defined as being type 1 if the enhancement 
increased by ≥1% from 4-8 minutes (slope >0.25%/minute), type 3 if the 
enhancement decreased by ≥1% from 4-8 minutes (slope < -
0.25%/minute), and type 2 if the enhancement neither increased nor 
decreased (slope between -0.25% and +0.25%/minute).  
7 
FDG PET/CT Image Analysis 
The tumour VOI was defined as all voxels with a Standardised Uptake 
Value (SUV) greater than 2.5 [9] within both lungs; this could include 
discontiguous volumes in diffuse disease. This was edited using tools 
within MIM software version 5 (MIMvista Corp., Cleveland, Ohio, USA), to 
remove physiological areas of uptake such as myocardium (figure 2). The 
following parameters were derived from the images: maximum SUV 
(SUVmax), Metabolic Tumour Volume (MTV) and Total Lesion Glycolysis 
(TLG = MTV x mean SUV). 
Statistical analysis 
Statistics were calculated using the statistical package R [10]. Baseline 
comparisons between DCE-MRI and PET/CT measurements were carried 
out on all patients, while survival analysis and comparison with 
progression-free survival were carried out on chemotherapy patients. 
Kaplan-Meier estimates for OS were generated using the survival package 
of R [11]. Significance of differences in Kaplan-Meier analysis was tested 
using the log-rank test. Kaplan-Meier statistics were calculated comparing 
values above and below group median for TLG, SUVmax, MTV and 
IAUC90, and comparing slope types for DCE-MRI washout curves. A p 
value of 0.05 was taken to be significant, and multiple comparisons were 
corrected for using the Holm-Bonferroni correction. 
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Results 
Patients 
73 patients were recruited between September 2008 and December 2011; 
58 were recruited to the chemotherapy arm and 15 to the comparator arm. 
Of these, 65 had baseline PET/CT (51 chemotherapy arm; 4 withdrew from 
the trial, 3 were unable to tolerate scans, and 1 was too unwell) and 61 had 
baseline DCE-MRI scans available (50 chemotherapy arm; 4 sets of data 
were unable to be analysed for technical reasons). 54 patients had follow-
up PET/CT (41 chemotherapy arm; 4 had problems with chemotherapy, 1 
was unable to tolerate scans, 3 were too unwell, 1 died, 2 corrupted scans) 
and 47 had follow-up DCE-MRI available for analysis (37 chemotherapy 
arm; 7 studies were unable to be analysed). Median follow-up time was 892 
days (IQR 605-1144 days); 12 patients were alive at the time of analysis. 
Patient characteristics are shown in table 1. 
Clinical Outcomes 
Median survival from consent to death in the chemotherapy group was 368 
days (IQR 195–526) and in the comparator group 325 days (IQR 176–458) 
equating to 12.3 and 10.8 months, respectively (p=.40). The number of 
chemotherapy cycles delivered was determined by oncologists using 
standard clinical assessment without access to serum biomarkers or 
PET/CT results. 87% of patients in the chemotherapy group received two or 
more cycles, 64% received four or more cycles and 36% received six 
cycles. Histological subtype was a strong independent predictor of survival, 
with epithelioid histology associated with a median survival of 456 (IQR 
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303–609) days compared with 197 (IQR 155–239) days (p<0.001) in 
patients with non-epithelioid histology. 
Comparison between PET/CT and DCE-MRI 
Baseline measurements from PET/CT and DCE-MRI were compared with 
each other for all patients, treated and control group. From PET/CT, 
SUVmax, TLG and MTV were correlated (p<.0001) and from DCE-MRI 
IAUC90 and Washout slope were correlated (p=.003). There were no 
significant correlations of SUVmax with IAUC90 (figure 3, r=.25, p=.055) or 
Washout Slope (figure 4, r=-.17, p=.19), MTV with IAUC90 (r=.12, p=.36) or 
Washout slope (r=-.14, p=.30), or TLG with IAUC90 (r=.15, p=.27) or 
washout slope (r=-.16, p=.22). There were no significant correlations when 
subgroups were tested with or without pleurodesis, or with epithelioid or 
non-epithelioid histology.  
Comparison with overall survival 
Baseline measurements from PET/CT and DCE-MRI were compared with 
overall survival for treated patients. 
From Univariate Cox Regression analysis, the only significant factors were 
histology and SUVmax, MTV and TLG from PET/CT (table 2). In 
multivariate analysis, if histology was included no other factors were 
significant; if histology was excluded then SUVmax was most significant. 
All PET/CT measurements showed a significant relationship with overall 
survival by Kaplan-Meier analysis, comparing values above and below 
median.  SUVmax above median (10.6) had OS 268 (177-481) days, below 
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median 525 (270-735) days (p=0.001) (figure 5); MTV above median (460 
mm3) had median OS 264 (IQR 177-439) days, below median MTV had 
median OS 562 (274-735) days (p=0.0001); and TLG above median (1806 
SUV-mm3) had OS 264 (177-439) days, below median 562 (274-735) days 
(p=0.0001). 
For DCE-MRI, baseline IAUC90 was not significantly related to OS (figure 
6); iAUC90 above median (88 %-min) gave median OS 270 (IQR 232-507) 
days, below median 506 (250-735) days (p=0.07). Washout slope was 
significantly related to OS (figure 7): type 1 (n=13) median OS 562 days 
(IQR 481-872) days, type 2 (n=6) median OS 256 days (IQR 104-498 
days), type 3 (n=31) median OS 274 (204-525) days; p=0.023. 
Combining PET/CT SUVmax and DCE-MRI Washout slope gave additional 
information (table 3). Those with SUVmax <10.6 and type 1 curves had the 
longest survival, median OS 735 days, SUVmax<10.6 and type 2 or 3 
curves had median OS 426 and 401 days, while patients with 
SUVmax>10.6 had median OS 312, 130 and 268 days for type 1, 2 and 3 
curves respectively (p=.009). Numbers in each group were too small to 
calculate confidence intervals for OS. 
There was no significant difference in OS between those who had and had 
not had pleurodesis. 
Comparison with Progression from CT  
Change in PET/CT (SUVmax, MTV and TLG) and DCE-MRI (IAUC90, 
Washout slope) were compared with progression-free survival at 8 weeks 
(table 4), 15 weeks (table 5), and 12 months (table 6). Change in washout 
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slope at 7-9 weeks and MTV and TLG at 9 months were significant at the 
p<.05 level, though correcting for multiple comparisons these were not 
significant (p<.003 required for 15 comparisons). 
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Discussion 
MRI of the lungs is difficult due to breathing-related motion artefact. As a 
consequence of this, the slice on which the analysis is carried out moves 
relative to the tumour between time-points, and so the enhancement-time 
curves were somewhat noisy. However, the advantage of using the area 
under the curve and the washout slope is that the effect of movement on 
these measurements should be limited, as movement will effectively be 
smoothed out. PET/CT is also subject to movement, which can be seen 
from the mismatch between the PET and the CT particularly at the lung 
bases. This will cause the uptake to be somewhat smoothed, with a 
potential reduction in SUVmax. This should have limited effect on the 
volumetric measures in most case, unless the uptake is close to the 
threshold. A fixed SUV threshold was used to analyse PET images as this 
is a method which is widely available, and does not require specialised 
software. The other method most widely used, a threshold at around 40% 
of maximum, would not be appropriate for diffuse tumour, as this is a 
method which has been validated for discrete solid tumours. In some cases 
there was visible tumour on PET/CT which was below the threshold of 
SUV=2.5 and so was not included in the MTV. However, these cases would 
have low FDG uptake however measured, which would be correlated with 
relatively long survival times.  
The analysis used for PET was fully 3D and took account of all active 
tumour throughout both lungs. On the other hand, the method for MRI was 
based on analysis of data from a single slice through the largest volume of 
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tumour. The largest tumour volumes corresponded for MRI and PET, 
however the SUVmax did not necessarily lie at the same point as the 
centre of the MRI ROI, although it often would have done. It would clearly 
be preferable to have used more comparable 3D analysis methods in both 
cases. However, the different measurements from PET/CT, SUVmax, MTV 
and TLG, were strongly correlated, suggesting that the overall tumour 
function can be measured using a measurement of uptake at a single 
voxel.   This suggests that the difference between 2D and 3D analysis may 
not be too significant in this case.  There was also no attempt to register 
studies before and after treatment, and image analysis was performed 
separately for pre and post-treatment studies. 
Probably of most importance is the different physiological and pathological 
meaning of the results. DCE-MRI is a measure of perfusion, while FDG-
PET/CT is a measure of metabolism. The results indicate that more active 
tumour tends to have higher perfusion, but that the metabolism from 
SUVmax or TLG is more significantly related to overall survival. SUVmax 
from PET/CT and curve-shape from DCE-MRI were combined (table 3); in 
this case, SUVmax was the most significant factor, as patients with 
SUVmax < median (10.6) had longer survival than those with SUVmax > 
median for all DCE-MRI curve shapes, but within this curve shape 1 
generally gave longer survival than curve shapes 2 or 3. 
A number of previous studies [9, 13-20], mostly retrospective and 
observational, have considered the relationship between survival and PET 
measurements at baseline. Of these, 8 studies [13-20] with a total of 594 
patients found that high SUVmax or TLG at baseline indicated worse 
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survival, and one with 41 patients [9] found no relationship. Three studies 
have considered percentage change in SUVmax, TLG and MTV after 
chemotherapy; two [9,12] with a total of 64 patients found that a percentage 
reduction in TLG was indicative of better OS, while one [20] with 131 
patients found a percentage reduction in SUVmax was related to longer 
OS. Prior pleurodesis has also been indicated as an issue, causing raised 
SUVmax in some studies [21, 22], but this was not found in our study. 
Previous work on the use of DCE-MRI in MPM used a pharmacokinetic 
modelling method to analyse studies on 19 patients with epithelioid 
histology, and showed longer OS for patients with a lower redistribution rate 
constant [6,7] though this was not significant.  
The utility of DCE-MRI in MPM with enhancement-time curves and curve-
based analysis is well established in breast cancer trials [23], while the 
curve shape and particularly the washout slope are used in clinical 
assessment of DCE-MRI studies in breast cancer [24]. Currently DCE-MRI 
is not used in routine clinical practice in evaluating lung or pleural 
malignancy. It has not been extended into clinical practice partly due to 
technical difficulties of respiration and the complex morphological 
characteristics of the lesions. In this study there was a trade-off between 
anatomical coverage and temporal resolution. Dynamic sequences were 
acquired for up to 12 minutes in order to assess washout, but shorter frame 
times would be better for analysis of initial enhancement. 
Quantification of DCE-MRI has only occasionally been carried out in MPM.  
One reason may be the complexity of the pharmacokinetic approach. We 
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have shown that it is possible to derive measurements from DCE-MRI 
without specialised software or acquisition parameters. Simple curve-based 
measurements from DCE-MRI have been shown to be related to 
pharmacokinetic measurements which can be generated from model-based 
analysis [25], while pharmacokinetic measurements have been shown to be 
correlated with microvascular density in MPM [7].  
The SWAMP study recruited patients from 7 centres. However, PET/CT 
imaging was only available at one centre, so all PET and MRI imaging was 
carried out there. This created issues for recruitment and follow-up imaging, 
due to the poor health of the participants and the distance from some 
recruiting centres. There were also some issues with archiving of image 
data, particularly for DCE-MRI. There were still sufficient numbers for 
analysis, but subgroup analysis, for example by histology, was more 
difficult. In the MRI studies due to the fairly long frame length used (45-
55s), information may have been lost about initial enhancement, although 
this should not have affected the analysis used of initial area under curve 
and washout slope significantly. The MRI studies were carried out on a 1T 
scanner, and a more modern 3T scanner would be able to image the lungs 
with a shorter frame time. Due to underlying disease, breath holding was 
difficult, so the bases of the lungs particularly were affected by movement. 
Other semi-quantitative measures for DCE-MRI have been proposed, 
including pharmacokinetic analysis, and it is possible that different 
methodology might make a difference. Alternatively, perfusion could be 
assessed by using contrast enhanced CT, which could be carried out as 
part of the PET/CT study. It would be of interest to compare the results of 
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perfusion assessment from CT and DCE-MRI in these patients. MRI will 
often be used as part of the diagnostic or patient management pathway, 
and in this case it might be appropriate to include assessment of DCE-MRI. 
Conclusion 
We have demonstrated that FDG-PET/CT and DCE-MRI can be quantified 
using relatively simple methods in a clinical setting, and that DCE-MRI 
carried out before treatment may offer prognostic information additional to 
that from FDG PET/CT. Baseline measurements of SUVmax, MTV and 
TLG from FDG PET/CT were significantly related to overall survival. 
Baseline washout curve shape from DCE-MRI was significantly related to 
overall survival, and offered additional prognostic information when 
combined with PET/CT, although the PET/CT result was more clinically 
significant. No measurements of change after treatment from FDG PET/CT 
or DCE-MRI were related to progression-free survival, so PET/CT and 
DCE-MRI are not recommended for follow-up in MPM.  
PET/CT gives prognostic information in Malignant Pleural Mesothelioma. 
DCE-MRI gives some prognostic information, but PET/CT should be used 
instead of DCE-MRI where available. 
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Figure Captions: 
Figure 1A MRI axial image showing region drawn over whole of tumour. 
Figure 1B Intensity vs frame curve from DCE-MRI study. 
Figure 2 FDG PET/CT showing axial, sagittal and coronal planes through 
the tumor, and MTV definition at above SUV threshold of 2.5 
Figure 3 Comparison of Integrated Area Under the first 90 seconds of the 
DCE-MRI enhancement-time curve (iAUC90) with the SUVmax. 
Figure 4 Comparison of Washout rate (%/minute) of the DCE-MRI 
enhancement-time curve with the SUVmax. 
Figure 5 Kaplan Meier analysis, chemotherapy patients, for SUVmax with 
Overall Survival. 
Figure 6 Kaplan Meier analysis, chemotherapy patients, for iAUC90 with 
Overall Survival. 
Figure 7 Kaplan Meier analysis, chemotherapy patients, for washout curve 
shape with Overall Survival. 
Figure 8 Kaplan Meier analysis, chemotherapy patients, for SUVmax and 
washout curve shape with Overall Survival. 
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Table Captions: 
Table 1. Patient characteristics. Key: CT – computed tomography; IMIG – 
International Mesothelioma Interest Group; TNM – Tumour Node 
Metastasis stage; WHO World Health Organisation. 
Table 2. Cox regression analysis. * indicates statistical significance. 
Multivariate analysis was carried out without Histology. 
Table 3. Kaplan-Meier analysis of a combination of SUVmax from PET/CT 
and washout slope from DCE-MRI for treated patients, based on survival 
time from trial entry to death. 
Table 4: Change of PET/CT and DCE-MRI parameters post-treatment 
compared for patients with disease progression and progression-free at 7-9 
weeks post-trial commencement. 
Table 5. Change of PET/CT and DCE-MRI parameters post-treatment 
compared for patients with disease progression and progression-free at 15 
weeks post-trial commencement. 
Table 6. Change of PET/CT and DCE-MRI parameters post-treatment 
compared for patients with disease progression and progression-free at 9 
months post-trial commencement. 
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 Chemotherapy arm Comparator arm 
Number of patients 58 (6 female) 15 (4 female) 
Age (median(IQR)) 69 (65-73) 77 (68-80) 
Talc pleurodesis before trial entry 21 (36%) 6 (40%) 
Histology   
Epithelioid 39 (67%) 11 (73%) 
Sarcomatoid 15 (26%) 0 (0%) 
Biphasic 4 (7%) 4 (26%) 
Baseline WHO PS   
0 17 (29%) 2 (13%) 
1 37 (64%) 11 (73%) 
2 4 (7%) 2 (13%) 
CT IMIG TNM stage   
I 7 (12%) 1 (7%) 
II 4 (7%) 1 (7%) 
III 28 (48%) 6 (40%) 
IV 19 (33%) 7 (47%) 
Table 1. Patient characteristics. CT – computed tomography; IMIG – International Mesothelioma 
Interest Group; TNM – Tumour Node Metastasis stage; WHO World Health Organisation. 
 Univariate  Multivariate  
OS analysis p-value HR (95% CI) p-value HR (95% CI) 
Histology - 
Sarcomatoid 
<0.0001* 3.9 (2.0-7.8)   
Histology - 
Biphasic 
0.0003* 8.5 (2.6-27.2)   
Pleurodesis 0.73 0.90 (0.49-1.64)   
SUVmax 0.005* 1.10 (1.03-1.17) 0.046 1.08 (1.00 – 1.16) 
MTV 0.0009* 1 (1-1.001) 0.12 1.0013 (0.9997-
1.003) 
TLG 0.002* 1 (1.00 – 1.00) 0.25 1.00 (1.00-1.00) 
IAUC90 0.22 1.008 (0.995-1.02)   
Washout slope 0.144 0.89 (0.77-1.04)   
Table 2. Cox regression analysis. * significant. Multivariate analysis carried out without Histology. 
 
SUVmax Washout 
Slope Type 
N Events Median OS 95% LCL 95% UCL 
<10.6 1 8 4 735 562 NA 
<10.6 2 2 2 426 355 NA 
<10.6 3 15 11 401 232 NA 
>10.6 1 4 4 312 192 NA 
>10.6 2 4 4 130 93 NA 
>10.6 3 15 14 268 250 493 
Table 3. 
 
 
PFS 7-9 weeks (after three Progression  Progression free and alive  p-value 
25 
cycles)  
mean change  
 
mean change  
SUVmax -1.3 -2.4 0.40 
MTV (ml) -292 -430 0.45 
TLG (SUV-ml) -1502 -2065 0.54 
iAUC90 (%-min) -0.7 -10.8 0.32 
Washout Slope (%/min) -0.4 1.2 0.03 
Table 4. 
 
 
PFS 15 weeks (after 
chemo) 
Progression  
 
mean change  
Progression free and alive 
 
Mean change  
P-value  
SUVmax -1.7 -2.1 0.81 
MTV (ml) -386 -383 0.99 
TLG (SUV-ml) -1871 -1900 0.98 
iAUC90 (%-min) -0.6 -15.5 0.14 
Washout Slope (%/min) 0.01 1.3 0.13 
Table 5. 
 
 
PFS 9 months  Progression  
 
mean change  
Progression free and alive 
 
Mean change  
p-value 
SUVmax -2.4 -0.4 0.22 
MTV (ml) -463 -151 0.02 
TLG (SUV-ml) -2304 -628 0.01 
iAUC90 (%-min) -5.8 -14.9 0.37 
Washout Slope (%/min) 0.28 1.78 0.31 
Table 6. 
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